Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma Journal Article

   

Authors:	Ellingson, B. M.; Abrey, L. E.; Nelson, S. J.; Kaufmann, T. J.; Garcia, J.; Chinot, O.; Saran, F.; Nishikawa, R.; Henriksson, R.; Mason, W. P.; Wick, W.; Butowski, N.; Ligon, K. L.; Gerstner, E. R.; Colman, H.; de Groot, J.; Chang, S.; Mellinghoff, I.; Young, R. J.; Alexander, B. M.; Colen, R.; Taylor, J. W.; Arrillaga-Romany, I.; Mehta, A.; Huang, R. Y.; Pope, W. B.; Reardon, D.; Batchelor, T.; Prados, M.; Galanis, E.; Wen, P. Y.; Cloughesy, T. F.
Article Title:	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma
Abstract:	Background. In the current study, we pooled imaging data in newly diagnosed glioblastoma (GBM) patients from international multicenter clinical trials, single institution databases, and multicenter clinical trial con-sortiums to identify the relationship between postoperative residual enhancing tumor volume and overall survival (OS). Methods. Data from 1511 newly diagnosed GBM patients from 5 data sources were included in the current study: (i) a single institution database from UCLA (N = 398; Discovery); (ii) patients from the Ben and Cathy Ivy Foundation for Early Phase Clinical Trials Network Radiogenomics Database (N = 262 from 8 centers; Confirmation); (iii) the chemoradiation placebo arm from an international phase III trial (AVAglio; N = 394 from 120 locations in 23 countries; Validation); (iv) the experimental arm from AVAglio examining chemoradiation plus bevacizumab (N = 404 from 120 locations in 23 countries; Exploratory Set 1); and (v) an Alliance (N0874) phase I/II trial of vorinostat plus chemoradiation (N = 53; Exploratory Set 2). Postsurgical, residual enhancing disease was quantified using T1 subtraction maps. Multivariate Cox regression models were used to determine influence of clinical variables, O6-methylguanine-DNA methyltransferase (MGMT) status, and residual tumor volume on OS. Results. A log-linear relationship was observed between postoperative, residual enhancing tumor volume and OS in newly diagnosed GBM treated with standard chemoradiation. Postoperative tumor volume is a prognostic factor for OS (P < 0.01), regardless of therapy, age, and MGMT promoter methylation status. Conclusion. Postsurgical, residual contrast-enhancing disease significantly negatively influences survival in patients with newly diagnosed GBM treated with chemoradiation with or without concomitant experimental therapy. © The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
Keywords:	bevacizumab; clinical trials; gbm; prognosis; contrast-enhancing tumor volume; t1 subtraction; new glioblastoma
Journal Title:	Neuro-Oncology
Volume:	20
Issue:	9
ISSN:	1522-8517
Publisher:	Oxford University Press
Date Published:	2018-09-01
Start Page:	1240
End Page:	1250
Language:	English
DOI:	10.1093/neuonc/noy053
PROVIDER:	scopus
PMCID:	PMC6071654
PUBMED:	29660006
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055446413&doi=10.1093%2fneuonc%2fnoy053&partnerID=40&md5=7ded710324392f98c330997dde811cac
Notes:	Article -- Export Date: 3 December 2018 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/134843